Bacteriology

RETEGO Labs: Bacterial Risk Entering Commercial Buildings After COVID Vacancy

Retrieved on: 
Thursday, July 29, 2021
Other Health, Utilities, Energy, Technology, Commercial Building & Real Estate, Construction & Property, Environment, Science, Urban planning, Building Systems, Other Technology, Health, Other Science, Water, Microbiology, Earth sciences, Environmental soil science, Bacteriology, Water pollution, Waterborne diseases, Biofilm, Water stagnation, Bacteria, Tap water

This decline in quality has been traced to stagnant water in the buildings.

Key Points: 
  • This decline in quality has been traced to stagnant water in the buildings.
  • Recent testing by RETEGO Labs has confirmed dangerously high bacterial levels (>106 cfu/mL, gross contamination) within building plumbing systems.
  • Although certain bacteria are always present in municipal water, they are typically controlled by the residual chlorine in the citys distribution system.
  • In unused and under-used buildings, stagnant organic material and bacteria can rapidly overcome residual chlorine and allow the growth of biofilm that harbors pathogens.

Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

Retrieved on: 
Thursday, July 29, 2021
Medical specialties, Branches of biology, Medicinal plants, Medicine, Bacteriology, Digestive system, Entheogens, Euphoriants, Prebiotic, Cannabis, Bifidobacterium, Medical cannabis

OTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc("Tetra" or the Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that itfiled a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Key Points: 
  • OTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc("Tetra" or the Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that itfiled a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.
  • GRAS status will allow for the broad application of this novel ingredient in foods as well as dietary supplements.
  • Research conducted through Tetra has shown that cannabis plant residue can increase the growth of beneficial gut microbes including bothLactobaccillus rhamnosusandBifidobacterium longum.
  • If granted, this patent application will provide Tetra with protection for the use of cannabis plant residue material containing residual cannabinoids within a specified profile range, as an oral prebiotic component alone or in combination with other pro, post, para, or prebiotics as a dietary supplement for gastrointestinal health.

The Biocodex Microbiota Foundation calls for Canadian proposals to study the microbiome’s role in health and diseases

Retrieved on: 
Wednesday, July 28, 2021
Microbiology, Microbiomes, Bacteriology, Branches of biology, Dutch inventions, Bacteria, Environmental microbiology, Microbiota, Microbiome, Human microbiome

The Biocodex Microbiota Foundations annual call for projects is part of a multi-year research initiative to further the understanding of the human microbiome.

Key Points: 
  • The Biocodex Microbiota Foundations annual call for projects is part of a multi-year research initiative to further the understanding of the human microbiome.
  • Biocodex currently holds 20 subsidiaries (including Biocodex Canada Inc. based in Montral Quebec) and multiple long-term partnerships spanning more than 124 countries.
  • The Biocodex Microbiota Foundation is a non-profit, general interest organization that supports research into microbiota and their interaction with various pathologies.
  • Projects investigating the implication of microbiota in human health are selected annually by committees of independent international scientists.

CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University

Retrieved on: 
Tuesday, July 27, 2021
Software, Biotechnology, Pharmaceutical, Health, Technology, University, Genetics, Education, Microbiology, Microbiomes, Bacteriology, Environmental microbiology, Branches of biology, Medical specialties, Microbiome, Human microbiome, Gut microbiota, Human Microbiome Project

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.

Key Points: 
  • CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.
  • The ability to study the human microbiome and its effects on human health is an area of great research interest and a pivotal application for OOC technology.
  • Modelling the human microbiome in the laboratory is challenging, especially since many of its several thousand strains of bacteria cannot grow or survive when exposed to oxygen.
  • Dr David Hughes, CEO, CN Bio, commented: We are rapidly coming to appreciate the important role the microbiome plays in human health and disease.

DSM acquires next-generation eubiotics platform start-up

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Natural sciences, Physical sciences, Microbiomes, Biomin, Biotechnology, Carbohydrate chemistry, Bacteriology, DSM, Gut microbiota, Shōjo Tsubaki, Midori

DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US$63m.

Key Points: 
  • DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US$63m.
  • Boston Massachusetts-based Midori has developed a technology platform that identifies glycans derived from natural food sugars that can precisely modulate how the gut microbiome functions in animals.
  • Such eubiotics can reduce the environmental footprint of animal farming and support the accelerated replacement of antibiotics in animal feed.
  • Midori's platform is highly synergetic with DSM's bioscience capability and current eubiotics portfolio, which was further strengthened through the acquisition of Biomin (as part of the Erber Group) .

Smidge Small Batch Supplements® Brand Launches, Offers Customers Premium Products In Minimalistic Form And A Holistic Approach To Health

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Bacteriology, Digestive system, Nutrition, Biotic, Vitamin, Probiotic, Health

SOUTHFIELD, Mich., July 26, 2021 /PRNewswire/ -- When it comes to health, minutia matters. That's the belief behind Smidge Small Batch Supplements® – formerly called Organic 3 – which recently launched a line of premium supplements that includes probiotics, digestive enzymes, whole food vitamins and natural minerals. The brand also introduced a more streamlined online shopping experience at GetSmidge.com.

Key Points: 
  • That's the belief behind Smidge Small Batch Supplements formerly called Organic 3 which recently launched a line of premium supplements that includes probiotics, digestive enzymes, whole food vitamins and natural minerals.
  • "At Smidge, we believe that food is medicine, you are what you digest and good nutrition is the root of wellness.
  • Everyone at Smidgehas a genuine, heartfelt concern for the well-being of our customers and their journey back to health.
  • Smidge Small Batch Supplementsthoroughly vets all raw materials, and all product ingredients are tested for potency, purity and nutritional value in third-party labs.

Phigenics Announces New Diagnostic To Detect Viable And Viable But Non-Culturable Legionella

Retrieved on: 
Monday, July 26, 2021
Legionellales, Bacteriology, Medical specialties, Legionella, Microbiology

WARRENVILLE, Ill., July 26, 2021 /PRNewswire/ -- Phigenics is pleased to announce a new diagnostic tool, PVT (Phigenics Validation Test) VIABLE (Viability Identification Assay by Legionella Enrichment).

Key Points: 
  • WARRENVILLE, Ill., July 26, 2021 /PRNewswire/ -- Phigenics is pleased to announce a new diagnostic tool, PVT (Phigenics Validation Test) VIABLE (Viability Identification Assay by Legionella Enrichment).
  • PVT VIABLE combines Polymerase Chain Reaction (PCR) detection and culture technology to rapidly detect all forms of viable Legionella bacteria found in building water systems in as little as 72 hours.
  • PVT VIABLE has the unique ability to differentiate dead Legionella from VBNC Legionella.
  • When used within an ANSI/ASHRAE 188 aligned WMP, this innovative diagnostic will help prevent disease and injury from Legionella infections associated with building water systems.We finally have a reliable, practical diagnostic that can detect viable Legionella AND VBNC Legionella with a very rapid turnaround time.

Probiotics Market by Application, Ingredient, Form, End User and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 23, 2021
General Health, Health, Fitness & Nutrition, Medical specialties, Bacteriology, Digestive system, Probiotics, Branches of biology, Clinical medicine, Dietary supplement, Biotic

The "Global Probiotics Market by Application (Functional Food & Beverages (Dairy Products, Non-dairy Beverages, Infant Formula, Cereals), Dietary Supplements, Feed), Ingredient (Bacteria, Yeast), Form (Dry, Liquid), End User, & Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Probiotics Market by Application (Functional Food & Beverages (Dairy Products, Non-dairy Beverages, Infant Formula, Cereals), Dietary Supplements, Feed), Ingredient (Bacteria, Yeast), Form (Dry, Liquid), End User, & Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global probiotics market is estimated to be valued at USD 61.1 billion in 2021 and is projected to reach USD 91.1 billion by 2026, at a CAGR of 8.3% during the forecast period.
  • Factors affecting the growth of the probiotics market are health benefits associated with probiotic-fortified foods and technological advancements in probiotic products.
  • Based on application, the food & beverages segment is estimated to account for the largest share in the probiotics market in 2020.

DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

Retrieved on: 
Friday, July 23, 2021
Medical specialties, Microbiology, Bacteriology, Bacterial diseases, Glycopeptide antibiotics, Gram-positive bacteria, Pathogenic bacteria, Dalbavancin, Antibiotics, Lipoglycopeptide, Staphylococcus aureus, Streptococcus pyogenes

NORTH CHICAGO, Ill., July 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE(dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.

Key Points: 
  • NORTH CHICAGO, Ill., July 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE(dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.
  • "This pediatric approval for DALVANCE as a single-dose provides a meaningful contribution to the treatment of children and infants with ABSSSI."
  • ABSSSI are bacterial infections of skin and associated tissues primarily caused by Gram-positive pathogens, including Staphylococcus aureus and Streptococcus pyogenes.
  • Results from the clinical trial in pediatric patients show that the safety findings of DALVANCE in pediatric patients were similar to those observed in adults.

Virtual Lecture on First-of-its-Kind Research Exploring the Influence of Pet Ownership on the Gut Microbiome

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Microbiomes, Microbiology, Bacteriology, Medical specialties, Environmental microbiology, Digestive system, Gut microbiota, Microbiota, Human microbiome, Cardiovascular disease, Microbiome

WASHINGTON, July 22, 2021 /PRNewswire-PRWeb/ --The Human Animal Bond Research Institute (HABRI) and IDEXX today hosted the fifth virtual lecture in the successful Human-Animal Bond Lecture Series, focused on the rationale and anticipated results of new, first-of-its-kind research exploring the influence of pet ownership on the gut microbiome and cardiovascular disease (CVD) risk in older adults.

Key Points: 
  • WASHINGTON, July 22, 2021 /PRNewswire-PRWeb/ --The Human Animal Bond Research Institute (HABRI) and IDEXX today hosted the fifth virtual lecture in the successful Human-Animal Bond Lecture Series, focused on the rationale and anticipated results of new, first-of-its-kind research exploring the influence of pet ownership on the gut microbiome and cardiovascular disease (CVD) risk in older adults.
  • This lecture, titled "The association of pet ownership, the gut microbiome, and cardiovascular disease risk among older adults", features Dr. Katharine Watson, MA, BVMS, discussing her active HABRI-funded study, "The influence of pet ownership on gut microbiota composition and cardiovascular disease risk among 50 to 85-year old United States adults".
  • The human microbiota is made up of trillions of cells, with the biggest populations residing in the gut.
  • Much of the science on the physical health benefits of pets involve the association between pet ownership and physical activity.